Shares of medical technology company Enovis Corporation (NYSE: ENOV) surged 6.72% in the pre-market session on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings report and upbeat guidance for 2025.
For the fourth quarter, Enovis reported adjusted earnings per share of $0.98, beating the consensus estimate of $0.92. Revenue for the quarter came in at $561 million, exceeding analysts' expectations of $555.1 million.
Looking ahead to 2025, Enovis provided an optimistic outlook, forecasting revenue in the range of $2.19 billion to $2.22 billion, which includes organic growth of 6% to 6.5%. This revenue guidance is largely in line with the consensus estimate of $2.22 billion. The company also expects adjusted earnings per share to be between $3.10 and $3.25, higher than the consensus estimate of $3.16.
In a separate announcement, Enovis revealed that its Chief Executive Officer, Matt Trerotola, has informed the Board of Directors of his intention to retire. The company has initiated a succession planning process and is actively working with an executive search firm to identify a growth-oriented MedTech leader to serve as the next CEO. Trerotola will continue to serve as an employee and Executive Advisor for one year after his successor is appointed to facilitate a smooth transition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.